19 documents found, page 1 of 2
World Heart Federation cholesterol roadmap: the Portuguese case
Abreu, Ana; Dores, Hélder; Gonçalves, Lino; Franco, Fátima; Silveira, Conceição; Proença, Gonçalo; Timóteo, Ana Teresa; Cardim, Nuno; Pedro, MónicaAtherosclerotic cardiovascular disease (ASCVD) remains the major cause of premature death and disability; effective cardiovascular (CV) risk prevention is fundamental. The World Heart Federation (WHF) Cholesterol Roadmap provides a framework for national policy development and aims to achieve ASCVD prevention. At the invitation of the WHF, a group of experts from the Portuguese Society of Cardiology (SPC), addr...
Of mice and man
Fiuza, ManuelaCisplatin-based chemotherapy is widely used in the treatment of various solid tumors, including ovarian, lung, bladder, and testicular cancers. The anticancer property of cisplatin is not completely understood. Increasing evidence indicates that the pathophysiological mechanisms are multifaceted, involving oxidative stress, DNA damage, alterations in signaling pathways, and direct myocardial damage.
Interventional cardiology in cancer patients: a position paper from the Portugu...
Menezes, Miguel Nobre; Tavares da Silva, Marta; Magalhaes, Andreia; Melica, Bruno; Toste, Júlia Cristina; Calé, Rita; Almeida, Manuel; Fiuza, ManuelaThe field of Cardio-Oncology has grown significantly, especially during the last decade. While awareness of cardiotoxicity due to cancer disease and/or therapies has greatly increased, much of the attention has focused on myocardial systolic disfunction and heart failure. However, coronary and structural heart disease are also a common issue in cancer patients and encompass the full spectrum of cardiotoxicity. ...
Cardiovascular health metrics differ between individuals with and without cancer
Kobo, Ofer; Abramov, Dmitry; Fiuza, Manuela; Chew, Nicholas W. S.; Ng, Cheng Han; Parwani, Purvi; Menezes, Miguel Nobre; Thavendiranathan, PaaladineshBackground: Although individuals with cancer experience high rates of cardiovascular morbidity, there are limited data on the potential differences in cardiovascular health (CVH) metrics between individuals with and without cancer. Methods and results: The National Health and Nutrition Examination Survey between 2015 and 2020 was queried to evaluate the prevalence of health metrics that comprise the American He...
Managing ischemic and bleeding risk in cancer patients presenting with acute co...
Fiuza, ManuelaCardiovascular disease (CVD) and cancer are the leading causes of death in developed countries. Improvements in early detection and major advances in cancer treatments have led to a growing number of survivors. However, cancer patients, including survivors, have a high risk for CVD that can be explained by multiple factors, including toxicity of cancer treatments (old and new drugs, chest radiotherapy), shared ...
Molecular changes in cardiac tissue as a new marker to predict cardiac dysfunct...
Ribeiro, Sónia; Simões, Ana Rita; Rocha, Filipe; Vala, Inês Sofia; Pinto, Ana Teresa; Ministro, Augusto; Poli, Maria Esmeralda; Diegues, Isabel MariaThe contribution of radiotherapy, per se, to late cardiotoxicity remains controversial. To clarify its impact on the development of early cardiac dysfunction, we developed an experimental model in which the hearts of rats were exposed, in a fractionated plan, to clinically relevant doses of ionizing radiation for oncological patients that undergo thoracic radiotherapy. Rat hearts were exposed to daily doses of ...
Subclinical left ventricular dysfunction detected by speckle-tracking echocardi...
Locquet, Médéa; Spoor, Daan; Crijns, Anne; van der Harst, Pim; Eraso, Arantxa; Guedea, Ferran; Fiuza, Manuela; Santos, Susana Constantino RosaBackground: In the case of breast cancer (BC), radiotherapy (RT) helps reduce locoregional recurrence and BC-related deaths but can lead to cardiotoxicity, resulting in an increased risk of long-term major cardiovascular events. It is therefore of primary importance to early detect subclinical left ventricular (LV) dysfunction in BC patients after RT and to determine the dose-response relationships between card...
Clinical experience of a cardio-oncology consultation at a tertiary university ...
Fiuza, Manuela; Magalhaes, Andreia; Menezes, Miguel Nobre; Costa, Paula; Ribeiro, Maria Leonor; Marques, Catarina; Brás, Raquel; Vieira, JoanaIntroduction: Heart disease and cancer are the two leading causes of morbidity and mortality worldwide. Advances in cancer screening and management have led to longer survival and better quality of life. Despite this progress, many cancer patients experience cardiovascular complications during and after cancer treatment. This study describes the experience of a cardio-oncology program at tertiary academic hospi...
Cost-effectiveness of cardio-oncology clinical assessment for prevention of che...
de Mello Sampayo, Felipa; Fiuza, Manuela; Pinto, Fausto J.; Fontes, JoanaIntroduction: Cancer chemotherapy increases the risk of heart failure. This cost-effectiveness study analyzes cardio-oncology imaging assessment of left ventricular ejection fraction (LVEF) using a Portuguese healthcare payer perspective and a five-year time horizon. Methods: Two cardioprotective strategies were assessed: universal cardioprotection (UCP) for all patients and cardioprotection initiated on diagno...
Lipoprotein(a) as a novel therapeutic target for preventing cardiovascular dise...
Fiuza, ManuelaResearch on the importance of lipoprotein(a) [Lp(a)] gained new momentum when it became a potential therapeutic target. Our understanding of this mysterious circulating lipoprotein particle has undergone advances and setbacks since its discovery in 1963 by Kåre Berg’s group.1 Lp(a) is composed of liver-derived apolipoprotein A and apolipoprotein B-100, and has a similar structure to both low-density lipoprotein...